Low-grade cardiac uptake on DPD bone scintigraphy warrants comprehensive evaluation as it may be due to underlying ATTR or AL cardiac amyloidosis and convey worse clinical outcomes #JACCIMG #HeartDisease #HeartFailure From @jaccjournals jacc.org/doi/10.1016/j.…

Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis | Circulation: Cardiovascular Imaging ahajournals.org/doi/10.1161/CI…

Dual pathology cardiac amyloidosis and mitral regurgitation is frequent and carries worse outcomes following mitral valve repair Dennis O'Reilly mitra langseth Gregor Heitzinger Philipp E. Bartko Andreas Kammerlander Matthias Koschutnik Julia Mascherbauer Kardiologie MedUni Wien Forschung AddThis | Home authors.elsevier.com/a/1fdFZ6uPJvmt…

In this short video, Dr. Carolina Donà talks about unveiling cardiac #amyloidosis, its characteristics and outcomes among patients w/ mitral regurgitation undergoing #TEER. 📃 #ESCCongress #JACCINT simpub paper: bit.ly/3pNUXVV #CardioTwitter #ACCIntl #vhdMR

🔴How prevalent is cardiac amyloidosis and which patients should be screened? Christian Nitsche European Society of Cardiology Journals #CardioEd #Cardiology #amyloidosis

Bioprosthetic valve dysfunction after #TAVI occurs at the same rate across the spectrum of life expectancy and is associated w/ higher mortality in patients w/ short but to not in those w/ the longest life expectancy #AorticStenosis #EHJCVI #Echofirst doi.org/10.1093/ehjci/…

Multiorgan blood biomarker abnormalities are common and associated with mortality in ATTR-CA. #AHAJournals Adam Ioannou ahajrnls.org/3wrNr9A

#Cardiacamyloidosis is a serious disease in which abnormal proteins accumulate in the #heart muscle and affect heart function. A team led by #MedUniVienna has now developed an #AI system that can automatically detect cardiac amyloidosis. ➡ bit.ly/3TINI1c The Lancet

NEW Research: Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac #amyloidosis using #ArtificialIntelligence: a retrospective, international, multicentre, cross-tracer development and validation study. Read it here: buff.ly/3VslXLv

Delighted to share our work on AI-based detection of cardiac amyloidosis on bone scintigraphy scans. ✅Removes interrater variability ✅Works across all amyloid tracers ✅Predicts outcome MedUni Wien Kardiologie MedUni Wien Forschung @CardiacImaging_BartsHeartCentre The Lancet Digital Health thelancet.com/journals/landi…

Presented at #ACC2024 and #SimPub in JACC Journals NT-proBNP progression and ODI detect disease progression and are associated with an increased risk of mortality in cardiac ATTR amyloidosis jacc.org/doi/10.1016/j.…

Expansion of the NAC staging system to detect early mortality in ATTR-CM🫀 Important for: 🔬clinical trial inclusion criteria 💊potential intensified treatment Adam Ioannou marianna fontana onlinelibrary.wiley.com/doi/10.1002/ej…

EASE-TAVR RCT: Targeted Management of Fluid Overload in Patients With Severe Aortic Stenosis Undergoing TAVR ✅️ improves clinical outcomes ✅️ improves quality of life #Cardiology #Valve JACC Journals Andreas Kammerlander Philipp E. Bartko heitzinn

#JACCINT is proud to honor Dr. Christian Nitsche w/ the Spencer King Award for Outstanding Scholarship for his groundbreaking research on managing fluid overload in pts w/ severe AS (EASE-TAVR)! 🎉 📎: jacc.org/doi/10.1016/j.… #ACC25 #TheFaceOfCardiology #TAVR #vhdAS Christian Nitsche

2/3_👥 N=226 (mean age 85) 🔹 71% had AVR (mostly TAVI) 🔹 32% received tafamidis 🔍 Results: Both AVR and tafamidis independently ↓ mortality Dual therapy (AVR + tafamidis) = best outcomes Survival similar to patients with lone AS undergoing AVR #EHJ #ValveDisease Christian Nitsche

3/3_🧠 Implication: Dual pathology (AS + ATTR-CA) should not preclude intervention. Combined AVR and disease-modifying therapy may restore prognosis. Non-randomised, but compelling signal for integrated treatment. @EurHeartJ #TAVR #Amyloidosis joao cavalcante Marco Merlo

🚨Excited to see the results of our transatlantic registry published in #EHJ. In dual aortic stenosis and ATTR-CM: treat the valve AND the myocardium. AVR and ATTR-specific medication ↓ mortality. doi.org/10.1093/eurhea… #CardioTwitter European Society of Cardiology Journals

Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Read more in the @EHJ at doi.org/10.1093/eurhea… #AorticValveReplacement #AmyloidosisAwareness @ESCardio European Society of Cardiology Journals

Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry tctmd.com/news/dual-appr…

#ESC2025 Check out this new meta-analysis that harmonizes data from all phase-3 trials assessing disease-specific Rx in ATTR-CM. There were early improvements in biomarkers, QoL & functional capacity, followed by⬇️CV events & ACM with continued treatment.🔗bit.ly/47UH3Z3